Another Late-Stage Firm with Impressive Technology and Promising Products

Iovance Biotherapeutics' Impressive Technology and Promising Products
About Iovance Biotherapeutics
Iovance Biotherapeutics (IOVA) is a late-stage biotechnology company developing novel cancer immunotherapies based on its tumor-infiltrating lymphocyte (TIL) technology. Iovance announced promising updates from ongoing clinical trials in advanced cervical cancer and advanced melanoma.

The data will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) between May 31, 2019 to June 4, 2019 in Chicago . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.